Literature DB >> 21851919

Visual acuity after laser in situ keratomileusis to correct high astigmatism in adults with meridional amblyopia.

Carolina Arruabarrena1, Miguel A Teus, José Luis Hernández-Verdejo, Rafael Cañones.   

Abstract

PURPOSE: To analyze the effect of laser in situ keratomileusis to correct high myopic astigmatism in patients with suboptimal best spectacle-corrected visual acuity (BSCVA).
DESIGN: Retrospective, interventional series of consecutive cases.
SETTING: Vissum Madrid, Madrid, Spain. PATIENTS: Two hundred five eyes of consecutive patients with suboptimal BSCVA and high myopic astigmatism of -3 diopters or more. INTERVENTION: Laser in situ keratomileusis surgery. MAIN OUTCOME MEASURES: BSCVA.
RESULTS: The BSCVA (decimal Snellen fraction notation) improved significantly (P = .0001) from a mean preoperative 0.77 ± 0.18 (range, 0.05 to 0.90) to 0.81 ± 0.19 (range, 0.05 to 1.25) 3 months after surgery. The mean change in lines of BSCVA (decimal Snellen fraction notation) was 0.04 ± 0.11 (range, -0.25 to 0.4). A significant inverse relationship (P = .001) was found between the preoperative BSCVA and the improvement in BSCVA.
CONCLUSIONS: In eyes with high myopic astigmatism and suboptimal preoperative BSCVA, laser in situ keratomileusis may result in a significant improvement in BSCVA.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21851919     DOI: 10.1016/j.ajo.2011.05.014

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Toric and toric multifocal IOLs in meridional amblyopia.

Authors:  Kirithika Muthusamy; Charles Claoué
Journal:  Int J Ophthalmol       Date:  2015-06-18       Impact factor: 1.779

Review 2.  Plasticity in the human visual cortex: an ophthalmology-based perspective.

Authors:  Andreia Martins Rosa; Maria Fátima Silva; Sónia Ferreira; Joaquim Murta; Miguel Castelo-Branco
Journal:  Biomed Res Int       Date:  2013-09-25       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.